Effect observation of Recombinant Human P53 Adenovirus Injection combined with regional heperthermia and chemotherapy treating advanced pancreatic cancer
FAN Yu-fei QIN Yuan LI Ding-gang
Department of Oncology,Beijing Yanhua Hospital,Beijing 102500,China
ObjectiveTo explore the effect of Recombinant Human P53 Adenovirus Injection combined with regional heperthermia and chemotherapy treating advanced pancreatic cancer.MethodsForty-eight patients with advanced pancreatic cancer treated by department of oncology in our hospital from July 2006 to July 2012 were retrospectively analyzed.Patients had moderate to massive ascites.These patients were divided into research group and control group according to different treatment methods.The research group:23 patients receivedgene therapy,Gemcitabine and Cisplatin chemotherapy,local hyperthermia.Control group:25 patients received Gemcitabine and Cisplatin systemic chemotherapy alone.The effect between two groups was compared.ResultsThe disease control rate was 78.26%in research group and it was 32.00%in control group,and the difference between the two groups was statistically significant(P＜0.05).The pain relief rate was 83.33%in the study group and it was 25.00%in control group and the difference was statistically significant between the two groups(P＜0.05).The incidence rate ofⅢ～Ⅳmyelosuppression was 21.74%in research group,and in was 24.00%in control group,and there was no statistical difference between the two groups(P＞0.05).ConclusionRecombinant Human P53 Adenovirus Injection combined with regional heperthermia and chemotherapy treating advanced pancreatic cancer can obtain higher disease control rate,effectively relief the pain,improve patients′quality of life,and without increasing bone marrow toxicity.
Malvezzi M，Bertuccio P，Levi F，et al.European cancer mortality predictions for the year 2014[J].Ann Oncol，2014，25（8）：1650-1656.
[2]
Jemal A，Murray T，Samuels A，et al.Cancer Statistics，2003[J].CA Cancer Clin，2003，53（1）：5-26.
[3]
De Witt J，Yu M，Al-Haddad MA，et al.Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA[J].Gastrointest Endosc，2010，71（2）：260-265.
[4]
Yonemori K，Okusaka T，Ueno H，et al.the efficacy of 5-fluorouracil（5-FU）plus cisplatin therapy for controlling malignant ascites in advanced pancreatic cancer patients[J]. Hepatogastroenterology，2007，54（80）：2383-2386.
[5]
汤钊猷.现代肿瘤学[M].2版.上海：上海医科大学出版社，2000：132-134.
[6]
Li D，Xie K，Wolff R，et al.Pancreatic cancer[J].Lancet，2004，363（9414）：1049-1057
[7]
Chen W，Zheng R，Zuo T，et al.National cancer incidence and mortality in China，2012[J].Chin J Cancer Res，2016，28 （1）：1-11.
Yang ZX，Wang D，Wang G，et al.Clinical study o ecombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma[J].J Cancer Res Clin Oncol，2010，136：625-630.
[11]
Nishizaki M，Meyn RE，Levy LB，et al.Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo[J].Clin Cancer Res，2001，7（9）：2887-2897.
EsquivelJ，Sticca R，SugarbakerP，etal.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin：a consensus Statement[J].Ann Surg Oncol，2007，14 （1）：128-133.
京公网安备 11010502046607号